Newer Products Expected To Drive Growth In 2026-2032

研报英文原文证据摘录

Newer Products Expected To Drive Growth In 2026-2032

TD Cowen Pharmaceutical Industry Pulse AbbVie

Global Research July 2026

AbbVie Key Upcoming Events

Time Frame Event Type Product Comments

2026 Clinical ABBV-295 (amylin from Gubra) Full Phase I data in obesity

ABBV-969 (PSMA/STEAP1 ADC) Phase I PoC data in mCRPC

Bretisilocin Phase II data in MDD

Emraclidine Phase II dose escelation data in schizophrenia

Epkinly Phase III data in 1L DLBCL (interim)

Phase III data in 2L DLBCL (SCT-ineligible)

Etentamig Phase III ORR data in 3L+ MM (registrational)

Livmoniplimab Phase II data in 1L NSCLC

Lutikizumab Phase III data in HS (Q4 2026)

Lutikizumab + ravaglimab Phase II data in RA

Qulipta Phase III data in menstrual migaine prevention

Rinvoq Phase III data in HS (Q4 2026)

Skyrizi Phase III data H2H vs. Sotyktu in psoriasis (52-week data)

Ubrelvy Phase III data in menstrual migaine prevention

Regulatory Ententamig Regulatory submission for 3L+ MM (monotherapy)

Epkinly Regulatory approval for 2L FL (ex-US)

Regulatory submission for 1L DLBCL and 2L DLBCL (SCTI)

Rinvoq Regulatory submission/approval for Vitiligo (Q4 decision)

Skyrizi Approval for subcutaneous induction in CD

TrenibotE (TrenibotulinumtoxinE) Refiling for glabellar lines (manufacturing CRL received)

Tavapadon Approval for Parkinson's Disease (Q3 decision)

Source: Company data; clinicaltrials.gov; PCD = "Primary Completion Date"

EPS Estimated To Be Up 40% In 2026, Then Expect Gains Of +10-13% In 2027-2032

+10% Sales And +40% EPS Expected In 2026

In 2026, we estimate EPS to be $13.98 (+40%; +14% ex-IPR&D in 2025) on sales of

$67.3B (+10%). We forecast Humira sales of $2.9B WW and $1.7B in the U.S. We

estimate gross margin to remain flat at 84.0% in 2026. We forecast SG&A to increase